, Volume 60, Issue 5, pp 900–910 | Cite as

c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice




High-energy diets are among the main causes of the global epidemic of metabolic disorders, including obesity and type 2 diabetes. The mechanisms of high-energy-diet-induced metabolic disorders are complex and largely unknown. The non-receptor tyrosine kinase c-Abl plays an important role in adipogenesis in vitro but its role in vivo in the regulation of metabolism is still elusive. Hence, we sought to address the role of c-Abl in diet-induced obesity and obesity-associated insulin resistance.


The expression of c-Abl in different fat tissues from obese humans or mice fed a high-fat diet (HFD) were first analysed by western blotting and quantitative PCR. We employed conditional deletion of the c-Abl gene (also known as Abl1) in adipose tissue using Fabp4-Cre and 6-week-old mice were fed with either a chow diet (CD) or an HFD. Age-matched wild-type mice were treated with the c-Abl inhibitor nilotinib or with vehicle and exposed to either CD or HFD, followed by analysis of body mass, fat mass, glucose and insulin tolerance. Histological staining, ELISA and biochemical analysis were used to clarify details of changes in physiology and molecular signalling.


c-Abl was highly expressed in subcutaneous fat from obese humans and HFD-induced obese mice. Conditional knockout of c-Abl in adipose tissue improved insulin sensitivity and mitigated HFD-induced body mass gain, hyperglycaemia and hyperinsulinaemia. Consistently, treatment with nilotinib significantly reduced fat mass and improved insulin sensitivity in HFD-fed mice. Further biochemical analyses suggested that c-Abl inhibition improved whole-body insulin sensitivity by reducing HFD-triggered insulin resistance and increasing adiponectin in subcutaneous fat.


Our findings define a new biological role for c-Abl in the regulation of diet-induced obesity through improving insulin sensitivity of subcutaneous fat. This suggests it may become a novel therapeutic target in the treatment of metabolic disorders.


Adiponectin c-Abl Insulin resistance Nilotinib Obesity 



Brown adipose tissue


Chow diet


Conditional knockout


Chronic myelogenous leukaemia


Endoplasmic reticulum


Epidymal white adipose tissue


General linear model


High-fat diet


Insulin tolerance test


c-Jun amino-terminal kinase


Platelet-derived growth factor receptor


Phosphatidylinositol 3-kinase


Retinol-binding protein 4


Subcutaneous white adipose tissue



Supplementary material

125_2016_4202_MOESM1_ESM.pdf (591 kb)
ESM(PDF 590 kb)


  1. 1.
    Ng M, Fleming T, Robinson M et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:766–781CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128CrossRefPubMedGoogle Scholar
  3. 3.
    Zimmet P, Thomas CR (2003) Genotype, obesity and cardiovascular disease--has technical and social advancement outstripped evolution? J Intern Med 254:114–125CrossRefPubMedGoogle Scholar
  4. 4.
    Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806CrossRefPubMedGoogle Scholar
  5. 5.
    Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–1428CrossRefPubMedGoogle Scholar
  6. 6.
    Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846CrossRefPubMedGoogle Scholar
  7. 7.
    Cnop M, Landchild MJ, Vidal J et al (2002) The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51:1005–1015CrossRefPubMedGoogle Scholar
  8. 8.
    Tran TT, Kahn CR (2010) Transplantation of adipose tissue and stem cells: role in metabolism and disease. Nat Rev Endocrinol 6:195–213CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sirvent A, Benistant C, Roche S (2008) Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 100:617–631CrossRefPubMedGoogle Scholar
  10. 10.
    Xiao L, Chen D, Hu P et al (2011) The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J Neurosci 31:9611–9619CrossRefPubMedGoogle Scholar
  11. 11.
    Liu W, Wu J, Xiao L et al (2012) Regulation of neuronal cell death by c-Abl-Hippo/MST2 signaling pathway. PLoS One 7:e36562CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wu R, Chen H, Ma J et al (2016) c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death. Cell Death Differ 23:542–552CrossRefPubMedGoogle Scholar
  13. 13.
    Greuber EK, Smith-Pearson P, Wang J, Pendergast AM (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13:559–571CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042CrossRefPubMedGoogle Scholar
  15. 15.
    Kantarjian H, Sawyers C, Hochhaus A et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652CrossRefPubMedGoogle Scholar
  16. 16.
    Barbany G, Hoglund M, Simonsson B, Swedish CMLG (2002) Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N Engl J Med 347:539–540CrossRefPubMedGoogle Scholar
  17. 17.
    Veneri D, Franchini M, Bonora E (2005) Imatinib and regression of type 2 diabetes. N Engl J Med 352:1049–1050CrossRefPubMedGoogle Scholar
  18. 18.
    Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC (2010) Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95:3763–3767CrossRefPubMedGoogle Scholar
  19. 19.
    Hagerkvist R, Jansson L, Welsh N (2008) Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond) 114:65–71CrossRefGoogle Scholar
  20. 20.
    Mokhtari D, Al-Amin A, Turpaev K et al (2013) Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5′-phosphatase interaction with c-Abl. Diabetologia 56:1327–1338CrossRefPubMedGoogle Scholar
  21. 21.
    Xia CQ, Zhang P, Li S et al (2014) C-Abl inhibitor imatinib enhances insulin production by beta cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. PLoS One 9:e97694CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Fitter S, Vandyke K, Gronthos S, Zannettino AC (2012) Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol 48:229–240CrossRefPubMedGoogle Scholar
  23. 23.
    Wilson B, Liotta LA, Petricoiniii E (2013) Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation. Mol Cell Proteomics 12:2522–2535CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Keshet R, Bryansker Kraitshtein Z, Shanzer M, Adler J, Reuven N, Shaul Y (2014) c-Abl tyrosine kinase promotes adipocyte differentiation by targeting PPAR-gamma 2. Proc Natl Acad Sci U S A 111:16365–16370CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    He W, Barak Y, Hevener A et al (2003) Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100:15712–15717CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Jeffery E, Berry R, Church CD et al (2014) Characterization of Cre recombinase models for the study of adipose tissue. Adipocyte 3:206–211CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84:277–359CrossRefPubMedGoogle Scholar
  28. 28.
    Arch JR, Hislop D, Wang SJ, Speakman JR (2006) Some mathematical and technical issues in the measurement and interpretation of open-circuit indirect calorimetry in small animals. Int J Obes 30:1322–1331CrossRefGoogle Scholar
  29. 29.
    Tschop MH, Speakman JR, Arch JR et al (2012) A guide to analysis of mouse energy metabolism. Nat Methods 9:57–63CrossRefGoogle Scholar
  30. 30.
    Boden G, Cheung P, Kresge K, Homko C, Powers B, Ferrer L (2014) Insulin resistance is associated with diminished endoplasmic reticulum stress responses in adipose tissue of healthy and diabetic subjects. Diabetes 63:2977–2983CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Han J, Murthy R, Wood B et al (2013) ER stress signalling through eIF2α and CHOP, but not IRE1α, attenuates adipogenesis in mice. Diabetologia 56:911–924CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    O’Rourke RW, Metcalf MD, White AE et al (2009) Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue. Int J Obes 33:978–990CrossRefGoogle Scholar
  33. 33.
    Bruun JM, Lihn AS, Pedersen SB, Richelsen B (2005) Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 90:2282–2289CrossRefPubMedGoogle Scholar
  34. 34.
    Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115:1111–1119CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Lee YH, Giraud J, Davis RJ, White MF (2003) c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 278:2896–2902CrossRefPubMedGoogle Scholar
  36. 36.
    Flamment M, Hajduch E, Ferre P, Foufelle F (2012) New insights into ER stress-induced insulin resistance. Trends Endocrinol Metab 23:381–390CrossRefPubMedGoogle Scholar
  37. 37.
    Fujikawa R, Ito C, Nakashima R, Orita Y, Ohashi N (2008) Is there any association between subcutaneous adipose tissue area and plasma total and high molecular weight adiponectin levels? Metab Clin Exp 57:506–510CrossRefPubMedGoogle Scholar
  38. 38.
    Nakamura Y, Sekikawa A, Kadowaki T et al (2009) Visceral and subcutaneous adiposity and adiponectin in middle-aged Japanese men: the ERA JUMP study. Obesity 17:1269–1273PubMedPubMedCentralGoogle Scholar
  39. 39.
    Bluher M, Williams CJ, Kloting N et al (2007) Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 30:3110–3115CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Steppan CM, Lazar MA (2002) Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 13:18–23CrossRefPubMedGoogle Scholar
  41. 41.
    McTernan PG, McTernan CL, Chetty R et al (2002) Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 87:2407CrossRefPubMedGoogle Scholar
  42. 42.
    Yang Q, Graham TE, Mody N et al (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356–362CrossRefPubMedGoogle Scholar
  43. 43.
    Meek SE, Nair KS, Jensen MD (1999) Insulin regulation of regional free fatty acid metabolism. Diabetes 48:10–14CrossRefPubMedGoogle Scholar
  44. 44.
    Hantschel O, Superti-Furga G (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 5:33–44CrossRefPubMedGoogle Scholar
  45. 45.
    Marley SB, Deininger MW, Davidson RJ, Goldman JM, Gordon MY (2000) The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 28:551–557CrossRefPubMedGoogle Scholar
  46. 46.
    Lee KY, Russell SJ, Ussar S et al (2013) Lessons on conditional gene targeting in mouse adipose tissue. Diabetes 62:864–874CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Chandalia M, Abate N (2007) Metabolic complications of obesity: inflated or inflamed? J Diabetes Complicat 21:128–136CrossRefPubMedGoogle Scholar
  48. 48.
    Le Q, Daniel R, Chung SW et al (1998) Involvement of C-Abl tyrosine kinase in lipopolysaccharide-induced macrophage activation. J Immunol 160:3330–3336PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Rong Wu
    • 1
    • 2
  • Jian-guang Sun
    • 1
    • 3
  • Ji-qiu Wang
    • 4
  • Binhua Li
    • 5
  • Qingsong Liu
    • 5
  • Guang Ning
    • 4
  • Wanzhu Jin
    • 6
  • Zengqiang Yuan
    • 1
    • 2
    • 7
  1. 1.State Key Laboratory of Brain and Cognitive SciencesInstitute of Biophysics, Chinese Academy of SciencesBeijingChina
  2. 2.College of Life SciencesUniversity of Chinese Academy of SciencesBeijingChina
  3. 3.Sino-Danish Center Neuroscience ProgramUniversity of Chinese Academy of SciencesBeijingChina
  4. 4.Ruijin Hospital Affiliated to Shanghai Jiaotong University School of MedicineShanghaiChina
  5. 5.High Magnetic Field LaboratoryChinese Academy of SciencesHefeiChina
  6. 6.Key Laboratory of Animal Ecology and Conservation Biology, Institute of Zoology, Chinese Academy of SciencesBeijingChina
  7. 7.Center of Alzheimerʼs Disease, Beijing Institute for Brain DisordersBeijingChina

Personalised recommendations